| Alan Drew Savoy, MD | |
|
1111 Ne 99th Ave, Suite 301, Portland, OR 97220-9428 | |
| (503) 963-2707 | |
| (503) 963-2802 |
| Full Name | Alan Drew Savoy |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 25 Years |
| Location | 1111 Ne 99th Ave, Portland, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306839543 | NPI | - | NPPES |
| 023129 | Medicaid | OR | |
| 8424921 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | MD61033900 (Washington) | Secondary |
| 207RG0100X | Internal Medicine - Gastroenterology | MD25943 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Portland Medical Center | Portland, OR | Hospital |
| Providence Milwaukie Hospital | Milwaukie, OR | Hospital |
| Providence Hood River Memorial Hospital | Hood river, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oregon Clinic Pc | 2860390408 | 319 |
News Archive
Researchers at Hospital for Special Surgery have identified a potential new target for drugs to treat patients with rheumatoid arthritis (RA), a protein known as IRHOM2. The finding could provide an effective and potentially less toxic alternative therapy to tumor necrosis factor-alpha blockers (TNF-blockers), the mainstay of treatment for rheumatoid arthritis, and could help patients who do not respond to this treatment. Efforts to develop drugs that hone in on this new target are underway.
Today's headlines include reports that the Centers for Medicare & Medicaid Services is stepping back from proposed changes to the Medicare drug program.
Advancements in technology and universal acceptance of the Internet have paved the way for major improvements in the healthcare industry. According to a recent report released by PricewaterhouseCooper's Health Research Institute in August 2009, 1.2 trillion healthcare dollars are wasted each year, with two of the main culprits being administrative inefficiency and redundant care.
Makefield Therapeutics, Inc., an emerging therapeutics company, today announced that it has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applications covering Makefield's biodegradable Hybrid Nanoparticles™, a versatile new drug delivery platform.
"The Global Vaccine Summit will be held on April 24 and 25 under the patronage of Sheikh Mohammed bin Zayed, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the Armed Forces, and in partnership with U.N. Secretary-General Ban Ki-moon and Bill Gates, co-chair of the Bill & Melinda Gates Foundation," The National reports.
› Verified 7 days ago
| Entity Name | Oregon Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265417174 PECOS PAC ID: 2860390408 Enrollment ID: O20031222000096 |
News Archive
Researchers at Hospital for Special Surgery have identified a potential new target for drugs to treat patients with rheumatoid arthritis (RA), a protein known as IRHOM2. The finding could provide an effective and potentially less toxic alternative therapy to tumor necrosis factor-alpha blockers (TNF-blockers), the mainstay of treatment for rheumatoid arthritis, and could help patients who do not respond to this treatment. Efforts to develop drugs that hone in on this new target are underway.
Today's headlines include reports that the Centers for Medicare & Medicaid Services is stepping back from proposed changes to the Medicare drug program.
Advancements in technology and universal acceptance of the Internet have paved the way for major improvements in the healthcare industry. According to a recent report released by PricewaterhouseCooper's Health Research Institute in August 2009, 1.2 trillion healthcare dollars are wasted each year, with two of the main culprits being administrative inefficiency and redundant care.
Makefield Therapeutics, Inc., an emerging therapeutics company, today announced that it has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applications covering Makefield's biodegradable Hybrid Nanoparticles™, a versatile new drug delivery platform.
"The Global Vaccine Summit will be held on April 24 and 25 under the patronage of Sheikh Mohammed bin Zayed, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the Armed Forces, and in partnership with U.N. Secretary-General Ban Ki-moon and Bill Gates, co-chair of the Bill & Melinda Gates Foundation," The National reports.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alan Drew Savoy, MD 541 Ne 20th Ave Ste 225, Portland, OR 97232-2895 Ph: (503) 963-2801 | Alan Drew Savoy, MD 1111 Ne 99th Ave, Suite 301, Portland, OR 97220-9428 Ph: (503) 963-2707 |
News Archive
Researchers at Hospital for Special Surgery have identified a potential new target for drugs to treat patients with rheumatoid arthritis (RA), a protein known as IRHOM2. The finding could provide an effective and potentially less toxic alternative therapy to tumor necrosis factor-alpha blockers (TNF-blockers), the mainstay of treatment for rheumatoid arthritis, and could help patients who do not respond to this treatment. Efforts to develop drugs that hone in on this new target are underway.
Today's headlines include reports that the Centers for Medicare & Medicaid Services is stepping back from proposed changes to the Medicare drug program.
Advancements in technology and universal acceptance of the Internet have paved the way for major improvements in the healthcare industry. According to a recent report released by PricewaterhouseCooper's Health Research Institute in August 2009, 1.2 trillion healthcare dollars are wasted each year, with two of the main culprits being administrative inefficiency and redundant care.
Makefield Therapeutics, Inc., an emerging therapeutics company, today announced that it has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applications covering Makefield's biodegradable Hybrid Nanoparticles™, a versatile new drug delivery platform.
"The Global Vaccine Summit will be held on April 24 and 25 under the patronage of Sheikh Mohammed bin Zayed, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the Armed Forces, and in partnership with U.N. Secretary-General Ban Ki-moon and Bill Gates, co-chair of the Bill & Melinda Gates Foundation," The National reports.
› Verified 7 days ago
Salona Shrestha, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 4805 Ne Glisan St, Portland, OR 97213 Phone: 503-215-2392 | |
Dr. Emmanuel Trungtoan Tavan, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2800 N Vancouver Ave, Suite 230, Portland, OR 97227 Phone: 503-413-2901 | |
Ginevra Lois Liptan, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 6400 Sw Canyon Ct, Ste 100, Portland, OR 97221 Phone: 503-477-9616 Fax: 503-477-9808 | |
Donald Richard Sullivan, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Uhn67, Portland, OR 97239 Phone: 503-494-6949 | |
Dr. Victor Nguyen Pham, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 9205 Sw Barnes Rd, Portland, OR 97225 Phone: 503-216-2906 | |
Richa Uppal, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 800 Sw 13th Ave, Portland, OR 97205 Phone: 503-221-0161 Fax: 503-274-1697 | |
Reem Hasan, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Ppv 350, Portland, OR 97239 Phone: 503-494-8562 |